Regencell Bioscience Holdings Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yat-Gai Au
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- First Commercial Building Causeway Bay Hong Kong KY1-1107
- IPO Date
- Jul 16, 2021
- CIK
- 0001829667
- Website
- regencellbioscience.com
- Similar Companies
- Business
- Regencell Bioscience Holdings Limited Regencell Bioscience Holdings Limited operates as an early-stage Traditional Chinese medicine (TCM) bioscience company focused on the research, development, and commercialization of liquid-based standardized TCM formulae for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD); the company offers three distinct formulae tailored for mild, moderate, and severe cases of ADHD and ASD patients, combining personalized natural herbs and compounds with modern scientific validation. Incorporated in 2014 and headquartered in Causeway Bay, Hong Kong, Regencell Bioscience Holdings Limited conducts its primary operations in Hong Kong, targeting patients, families, caregivers, and medical professionals with ongoing research studies and assistance programs limited to Hong Kong residents. In June 2025, the company executed a 38-for-1 forward stock split by capitalizing its share premium account, increasing outstanding ordinary shares to 494,488,908 as of June 30, 2025 without altering authorized capital or par value; it reported net losses of $3.58 million for fiscal 2025 amid continued R&D and administrative investments, with no approved products or commercial sales to date, and faced auditor emphasis on going concern risks alongside material weaknesses in internal controls.
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
RGC Resources, Inc. Declares Quarterly Dividend
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors
RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm
RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role
REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC
REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline